PubMed=9241074; DOI=10.1002/(SICI)1097-0142(19970801)80:3<401::AID-CNCR8>3.0.CO;2-U
Abdel-Wahab Z., Weltz C., Hester D., Pickett N., Vervaert C., Barber J.R., Jolly D.J., Seigler H.F.
A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response.
Cancer 80:401-412(1997)

PubMed=11520076; DOI=10.1006/cimm.2001.1809
Zennadi R., Abdel-Wahab Z., Seigler H.F., Darrow T.L.
Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells.
Cell. Immunol. 210:96-105(2001)

PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209
Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J., Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.
Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.
Cancer Res. 64:1157-1163(2004)